2026 ASH®
Annual Meeting & Exposition December 12-15, 2026 ▪ New Orleans, Louisiana

Paper Details

Abstracts, authors, affiliations, and disclosures.

Saturday, December 12, 2026
05:30 p.m. - 07:30 p.m.
MCCNO - Hall F
Access, Representation, Population Health, Treatment Considerations, Combination Therapy, Supportive Care, Biological Therapies, Transplantation, Monoclonal Antibody Therapy, Adverse Events, Biological Processes, Pathogenesis, Genomics, Microbiome, Clinical Practice (Health Services and Quality), Quality of Care, Diseases, Lymphoid Malignancies, Lymphoid Leukemias, Lymphomas, LGL, Hodgkin Lymphoma, Non-Hodgkin Lymphoma, B Cell Lymphoma, T Cell Lymphoma, Indolent Lymphoma, Aggressive Lymphoma, Research, Fundamental Science, Translational Research, Clinical Research, Clinical Trials, Epidemiology, Health Outcomes Research, Patient-Reported Outcomes, Real-World Evidence, Study Population, Human, Adult, Elderly
PAPER

1838 Treatment patterns and outcomes in angioimmunoblastic T-cell lymphoma: A 25-year population-based study from British Columbia

Jonathan Isenberg, MD, Aixiang Jiang, PhD2, Alina S. Gerrie, MD, FRCPC, MPH3, Diego Villa, MD4, Henry Ngu5, Christopher P. Venner, MD6, Andrew J. Cowan, MD7, Judith Rodrigo, MD, FRCPC8, Graham Slack9, David Scott, MD10, Kevin Song, MD11, Andrew Lytle, MD, PhD12, Laurie H. Sehn, MD13, Kerry Savage, MD, MSc, BSc14
1 Division of Medical Oncology, University of British Columbia and Centre for Lymphoid Cancer, BC Cancer, VANCOUVER, British Columbia, Canada
2 Division of Medical Oncology, University of British Columbia and Centre for Lymphoid Cancer, BC Cancer, VANCOUVER, British Columbia, Canada
3 Division of Medical Oncology, University of British Columbia and Centre for Lymphoid Cancer, BC Cancer, VANCOUVER, British Columbia, Canada
4 Division of Medical Oncology, University of British Columbia and Centre for Lymphoid Cancer, BC Cancer, VANCOUVER, British Columbia, Canada
5 Department of Hematology, Auckland City Hospital, Auckland, New Zealand
6 Division of Medical Oncology, University of British Columbia and Centre for Lymphoid Cancer, BC Cancer, VANCOUVER, British Columbia, Canada
7 Division of Medical Oncology, University of British Columbia and Centre for Lymphoid Cancer, BC Cancer, VANCOUVER, British Columbia, Canada
8 VGH, VANCOUVER, British Columbia, Canada
9 Department of Pathology and Laboratory Medicine, University of British Columbia and BC Cancer, BC Cancer, Vancouver, British Columbia, Canada
10 Division of Medical Oncology, University of British Columbia and Centre for Lymphoid Cancer, BC Cancer, VANCOUVER, British Columbia, Canada
11 VGH, VANCOUVER, British Columbia, Canada
12 Department of Pathology and Laboratory Medicine, University of British Columbia and BC Cancer, BC Cancer, Vancouver, British Columbia, Canada
13 Division of Medical Oncology, University of British Columbia and Centre for Lymphoid Cancer, BC Cancer, VANCOUVER, British Columbia, Canada
14 Division of Medical Oncology, University of British Columbia and Centre for Lymphoid Cancer, BC Cancer, VANCOUVER, British Columbia, Canada

Background Angioimmunoblastic T-cell lymphoma (AITL) is a rare T-follicular helper peripheral T-cell lymphoma associated with poor outcomes.  CHOP-based chemotherapy remains the front-line treatment standard, with controversy around the impact of brentuximab vedotin (BV-CHP) and of consolidative autologous stem cell transplant (ASCT). For relapsed/refractory R/R AITL, prior studies support allo-SCT as the favored approach. Herein, we evaluated treatment patterns and long-term outcomes at different time points in the disease course of AITL.

Methods All patients (pts) > 18 y with AITL were identified in the  BC Cancer Lymphoid Cancer Database to identify all patients (pts) > 18 years (y) diagnosed between 2000-2025.  Treatment eras considered were 2000-2010, 2011-2019, 2020-2025, to capture increased use of ASCT and novel therapies.  TTP (time to progression) (relapse/progression of lymphoma, death due to lymphoma or treatment toxicity) and overall survival (OS) were evaluated, the latter also in the R/R setting.  In those managed with curative intent, a competing-risk analysis was performed evaluating the cumulative incidence (CI) of relapse in pts event free at 24 m (EFS24) and to explore the impact of ASCT those event-free at 9m (EFS9).

Results In total, 237 pts were identified: De novo AITL in 221 pts; 15(6%) had a prior lymphoma. Overall, 97 pts (41%) had a pre-existing autoimmune disease (hematologic n=45, 21%; non-hematologic n=52, 24% (incl. 4 with both).

Median age was 70y (range 34-94),138 (58%) were male, 127 (54%) had PS > 2, 216 (93%) had stage 3/4 disease, 137 (58%) had B symptoms, LDH elevated 137 (58%).  Spleen 123 (52%) and extranodal involvement 147(62%) were common;152 (64%) had IPI ≥3.

Of 232 (98%) pts with treatment information, 165 (72%) were managed with curative intent, primarily CHOP-based chemotherapy (24, 14.5% ASCT), 11 (5%) received palliative-intent chemotherapy; 46 (20%) received steroids /no therapy;  six pts were observed (spontaneous remission n=4).

After a median follow-up of 8.6y (95% CI 5.8-11.3) the 5/10 y OS were 30%/20.3% respectively; 5/10 y TTP was 19.2% and 14.2%, respectively. There was no difference in TTP (p=0.57) or OS (p=0.60) by era. TTP was poor across all age groups, and inferior in those > 80 y (5 y: <60y 21.4%; 60-70y 19.7%, 71-8y 24.1%, >80, 6.1%) (p<0.001). OS was also worse in those > 80 y, but superior in those <60 y (5y 51.4%) in all pair-wise comparisons (5y: 60-70 y 34.5%; 71-80 y 26.1%, >80; 6.7%) (p<0.001 pooled log-rank).

Considering the 165 pts treated with curative-intent systemic therapy, the median age was 67y (34-85 y), 59% male, IPI>2 93%.  The 5 and 10y OS were 39.9% and 27%, respectively; 5 and 10y TTP were 25.8% and 18.7%, respectively.  Pts who received BV-CH(E)P (n=29) (median f/u 2.4 y) had a 2 and 5 y TTP of 57.9% and 25.3%, respectively. For those that reached EFS24 (n=57), the 5y cumulative incidence (CI) of relapse was 40.1% and 5y OS was 59.3%.

In total, 52/165 pts (31.5%) were intended to undergo ASCT (median age 60 y (34-73 y) following induction chemotherapy, a practice more common in the later eras (p<0.001). This group had a 5 y TTP and OS of 28.2% and 53%, respectively, and for the 24 pts (46.1%) that proceeded to ASCT, the 5y OS was 63.6%. To further evaluate the impact of ASCT, we compared those who received ASCT to all pts < 70 y (curative) that reached EFS9. There was a trend to a reduced risk of relapse with ASCT (5 y CI 35.7% vs 73%, p=0.087). 

Of the pts treated with curative intent, 111 had R/R disease with a median OS (mOS) of 7.7 m;  74 were had at least one cycle of systemic therapy (chemotherapy n=51; novel agent n=22; unknown n=1) and had a mOS of 1.2 y and 5 y OS was 31%.   For those intended for SCT (n=37) the mOS was 19.2 m and 5 y OS was 48.1%; for the 24 pts that received  SCT (Allo-SCT, n=19) , the 5 y post-SCT OS was 65.8% (5 y: allo-SCT 70.7% vs ASCT 50%, p=0.14) compared with a 5 y OS of 14.9% and mOS of 11.2 m for those not intended for SCT (p=0.003).

Conclusions In this real world analysis, outcomes in AITL were poor, including in pts treated with curative intent, even in the youngest age group. Further studies are needed clarifying the role of BV-CHP and ASCT.  For pts reaching EFS24, the CI  of relapse is ~40%, supporting prolonged follow-up.  For pts with R/R disease, outcomes are more favorable for those able to undergo SCT, especially allo-SCT, highlighting it’s important role management.
Jonathan Isenberg, MD: No relevant conflicts of interest to declare.